Korro Bio (NASDAQ:KRRO) Shares Down 4%

Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report)'s stock price fell 4% during trading on Thursday . The company traded as low as $66.06 and last traded at $66.52. 14,025 shares traded hands during trading, a decline of 49% from the average session volume of 27,381 shares. The stock had previously closed at $69.30.

Wall Street Analysts Forecast Growth

KRRO has been the topic of a number of research reports. Piper Sandler reissued an "overweight" rating and set a $180.00 target price on shares of Korro Bio in a report on Wednesday, March 27th. Royal Bank of Canada increased their target price on Korro Bio from $70.00 to $90.00 and gave the stock an "outperform" rating in a research report on Wednesday, March 27th. BMO Capital Markets restated an "outperform" rating and set a $120.00 price target on shares of Korro Bio in a research report on Tuesday, March 26th. Finally, HC Wainwright lifted their price objective on shares of Korro Bio from $100.00 to $115.00 and gave the company a "buy" rating in a research report on Thursday, March 28th.

Korro Bio Trading Down 3.6 %

The firm has a market cap of $535.58 million, a P/E ratio of -0.67 and a beta of 2.18. The business has a 50-day simple moving average of $63.33.

Institutional Investors Weigh In On Korro Bio

Several institutional investors have recently bought and sold shares of the stock. Atlas Venture Life Science Advisors LLC bought a new stake in shares of Korro Bio during the 4th quarter worth about $53,648,000. Eventide Asset Management LLC acquired a new stake in Korro Bio in the fourth quarter worth approximately $26,185,000. 72 Investment Holdings LLC acquired a new stake in Korro Bio in the fourth quarter worth approximately $13,269,000. Vanguard Group Inc. bought a new position in Korro Bio during the 4th quarter valued at $12,988,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Korro Bio during the 4th quarter valued at $12,741,000. Institutional investors and hedge funds own 13.18% of the company's stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc is based in Cambridge, Massachusetts.